Rucaparib
As of the edition of 20 October 2026, Rucaparib is a small molecule: marketed, first approved in 2016 (US); acts on PARP1, PARP2 and PARP3; US protection ends in 2031.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Rubraca
- First approved
- 19 December 2016 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- pharmaand
- Registered trials
- 63, 14 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Hormones; Skin and connective tissue; Digestive system
US protection
US protection ends in 2031.
The last listed US drug-substance patent ends in 2031. The application that gives this date is held by pharmaand.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product9 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 9 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Rucaparib.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 1 | 13 | 13 | 0 | 0 |
| Phase 2 | 39 | 16 | 6 | 14 |
| Phase 3 | 8 | 5 | 3 | 0 |
| All trials | 63 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| pharmaand | Acquired holder and Lead sponsor of trials | 2010 to now |
| Clovis Oncology | Originator | 2016 to 2024 |